Pharma & Biotech - Page 26

The pharmaceutical supply chain faces a persistent challenge: being “GS1-aligned” does not always mean a system has been independently validated against the standard. GS1 certification is emerging as a critical distinction for

Pharmaceutical and biotech companies are under mounting pressure to justify artificial intelligence investments, but the harder question is whether anyone is measuring if it actually works. A recent market survey of brand

Daiichi Sankyo has revised its full-year guidance upward after discovering an accounting error that understated operating profit in its fiscal year 2025 results. The Japanese pharmaceutical company identified a mistake in the

The pharmaceutical industry continues to wrestle with supply chain vulnerability, a problem that has intensified steadily since pandemic-era drug shortages first exposed critical weaknesses. Geopolitical tensions, tariff uncertainty, and ongoing national security

STEPLogic Trace is positioning itself as a key solution for pharmaceutical companies navigating the complex requirements of DSCSA-compliant supply chains. The platform helps pharmaceutical supply chains produce certified EPCIS outputs, enabling companies

Alnylam Pharmaceuticals (ALNY) shares collapsed nearly 28% on Thursday, closing at $206.88 after the company reported disappointing Amvuttra sales and slashed its full-year outlook. The RNA interference therapy crossed the $1 billion

Pharmaceutical companies are being urged to assess whether their serialization systems can keep pace with expanding business demands and regulatory requirements. Serialization has become a cornerstone of modern pharmaceutical supply chain management,

Pfizer (PFE) has announced that its drug Litfulo met primary goals in two large late-stage studies for nonsegmental vitiligo, the most common form of the skin-pigmentation disorder. Both studies showed significantly more

The US Food and Drug Administration has moved into full enforcement of the Drug Supply Chain Security Act after an 18-month stabilisation grace period concluded. The enforcement shift marks a significant turning

Ember LifeSciences has entered into a capital and business alliance with Alfresa Corporation to strengthen pharmaceutical cold chain logistics across Japan. Alfresa Corporation is a subsidiary of Alfresa Holdings Corporation, which holds